BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29493327)

  • 1. Good adherence to adjuvant endocrine therapy in early breast cancer - a population-based study based on the Swedish Prescribed Drug Register.
    Lundgren C; Lindman H; Rolander B; Ekholm M
    Acta Oncol; 2018 Jul; 57(7):935-940. PubMed ID: 29493327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
    Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
    Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
    Wigertz A; Ahlgren J; Holmqvist M; Fornander T; Adolfsson J; Lindman H; Bergkvist L; Lambe M
    Breast Cancer Res Treat; 2012 May; 133(1):367-73. PubMed ID: 22286315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
    Blanchette PS; Lam M; Richard L; Allen B; Shariff SZ; Vandenberg T; Pritchard KI; Chan KKW; Louie AV; Desautels D; Raphael J; Earle CC
    Breast Cancer Res Treat; 2020 Jan; 179(1):217-227. PubMed ID: 31571072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
    He W; Smedby KE; Fang F; Olsson H; Margolin S; Hall P; Czene K
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28423398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy use among Appalachian breast cancer survivors.
    Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
    Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy.
    Quinn EM; Fleming C; O'Sullivan MJ
    Ir J Med Sci; 2016 May; 185(2):383-92. PubMed ID: 25971465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
    Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
    Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain.
    Font R; Espinas JA; Barnadas A; Izquierdo A; Galceran J; Saladie F; Marcos-Gragera R; Torrent A; Manchon-Walsh P; Borras JM
    Breast Cancer Res Treat; 2019 Jun; 175(3):733-740. PubMed ID: 30887164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.
    Wulaningsih W; Garmo H; Ahlgren J; Holmberg L; Folkvaljon Y; Wigertz A; Van Hemelrijck M; Lambe M
    Breast Cancer Res Treat; 2018 Nov; 172(1):167-177. PubMed ID: 30030708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
    Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
    He W; Fang F; Varnum C; Eriksson M; Hall P; Czene K
    J Clin Oncol; 2015 Jul; 33(20):2262-9. PubMed ID: 26033800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.
    Kuba S; Ishida M; Nakamura Y; Taguchi K; Ohno S
    Breast Cancer; 2016 Jan; 23(1):128-133. PubMed ID: 24934610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
    Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
    J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
    Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
    J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence.
    Neuner JM; Fergestrom NM; Laud PW; Nattinger AB; Beyer KMM; Flynn KE; Pezzin LE
    Cancer; 2019 Nov; 125(22):3960-3965. PubMed ID: 31373689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to adjuvant endocrine therapy in women with breast cancer.
    Danilak M; Chambers CR
    J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
    Tervonen HE; Daniels B; Tang M; Preen DB; Pearson SA
    Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):812-820. PubMed ID: 30861596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
    Lee C; Check DK; Manace Brenman L; Kushi LH; Epstein MM; Neslund-Dudas C; Pawloski PA; Achacoso N; Laurent C; Fehrenbacher L; Habel LA
    Breast Cancer Res Treat; 2020 Feb; 180(1):219-226. PubMed ID: 31975315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.